Dual agonist: GLP-1 plus GIP: Tirzapeptide is a combination of GLP-1 RA and a GIP agonist that is FDA-approved for weight loss
[21] For patients undergoing surgery , the approach should be individualised based on several factors: Aspiration risk assessment : Patients with symptoms of gastroparesis, those on high doses, or those who have recently initiated therapy may have increased risk Type of surgery : Particularly procedures involving the gastrointestinal tract Indication for GLP-1 therapy : Whether for diabetes management or weight loss If GLP-1 medications are temporarily withheld based on individual risk assessment or local policy, patients with diabetes should have a clear plan for glycaemic management, including capillary glucose monitoring and potential bridging therapy, developed in consultation with the diabetes team
Many patients with obesity also have fatty liver disease
Ranking treatments in frequentist network meta-analysis works without resampling methods
Beyond thiopurines, the delayed gastric emptying induced by GLP-1RAs may theoretically affect other oral IBD medications
In the phase 2 study published in the New England Journal of Medicine, gastrointestinal symptom rates nearly doubled when participants jumped directly to 8mg instead of titrating gradually from 1mg
